The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection

Abstract

Supplemental Digital Content is available in the text

Development of a clinical scoring model to predict the overall and relapse‑free survival of patients with hepatocellular carcinoma following a hepatectomy

“…In addition, the HBV genotype is associated with tumor recurrence and genotype C results in greater tumor recurrence rate compared with genotype B (35). Furthermore, different antiviral drugs also result in significantly different prognoses in patients with HBV-associated HCC following hepatectomy (36)(37)(38); however, in the present study, patients were not divided into subgroups for further analysis according to HBV load, viral genotype and antiviral drugs. The present study established the AVLEM scoring system requiring only simple clinicopathological information (including ascites, vascular tumor thrombus, tumor differentiation level, extrahepatic metastasis and multiple lesions), which is a low-cost scoring model to predict recurrence and the OS of patients with HCC undergoing curative resection; however, this system has certain limitations.…”

The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments

“…The 14 selected studies were published between 2000 and 2019 and involved a total of 2481 patients. [ 9 – 11 , 14 , 18 , 21 , 22 , 37 – 43 ] The longest median follow-up duration was more than 120 months and the shortest median follow-up duration was 60 months. Study characteristics are summarized in Table 1 .…”

“…These studies were performed in 3 different countries (5 in Japan, [ 9 , 40 – 43 ] 8 in China mainland, [ 10 , 11 , 14 , 18 , 21 , 22 , 37 , 38 ] and 1 in the Korea [ 39 ] ); all studies were published in full text. The type of study design included 1 case–control studies, [ 40 ] 11 retrospective observational studies, [ 9 – 11 , 14 , 22 , 37 – 39 , 41 – 43 ] and 2 RCTs. [ 18 , 21 ]…”

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review

“…68 Of note, long-term adefovir therapy was associated with better overall survival and disease-free survival than long-term therapy with telbivudine in patients who had hepatectomy for HBV-related HCC. 69 Regarding the short-term post-operative complications after curative resection, perioperative antiviral therapy was found to reduce the patients’ recovery time and the improvement of the liver function compared to non-treatment groups. 70 The improvement of liver function and the progression-free survival after curative resection for HCC was found to be more likely in patients with HCC less than 3 cm in size.…”